Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Grant L, Fletcher M, Slack M, Hayford K, Hanquet G, Meroc E, Dobreva D, Baay M, Gessner B June 23, 2022 ISPPD 2022 Pneumococcal Disease

The epidemiological characteristics of PCV20nonPCV13 serotype disease among children

View Presentation
Poster
Hitchins LJ, Horne E, Robertson MC, Pojar S, Gould K, Hinds J, Murphy A, Peters T, Kerruish L, Howard A, Court J, Ambrose P, Elterish F, Nyazika TK, Mitsi E, Nikolaou E, Solórzano C, Gordon SB, Theilacker C, Begier E, Gessner BD, Ferreira DM June 23, 2022 ISPPD 2022 Pneumococcal Disease

The prevalence of Streptococcus pneumoniae serotypes in Liverpool between 2010-2021

View Presentation
Poster
Vietri J, Sato R, Weycker D, Averin A, Kumar M, Prasad S, Chilson June 23, 2022 ISPPD 2022 Pneumococcal Disease

Uptake of Pneumococcal Vaccine in US Adults following Shared Clinical Decision Making Recommendation for PCV13

View Presentation